Foot And Mouth Disease Vaccine Market Size to Exceed USD 5.66 Bn by 2032

The Foot And Mouth Disease Vaccine Market, estimated at USD 3.15 Bn in 2025, is expected to exhibit a CAGR of 8.7% and reach USD 5.66 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Market Dynamics:

Global foot and mouth disease vaccine market growth is driven by rising disease outbreak and rising consumption of animal products. FMD is highly contagious viral disease affecting cloven-hoofed animals including cattle and swine. Growing outbreak of disease has prompted governments and veterinary bodies to implement vaccination programs. According to the data published by FAO, around 80-90% of world's sheep, cattle and swine populations live in regions where foot and mouth disease is endemic. Furthermore, increasing demand for animal protein such as meat and dairy has led to rise in livestock population, thus, increasing the risk of contracting FMD virus. As the production of milk, eggs and meat involves gathering of animals in close contact, the disease spreads more rapidly. Vaccination plays a crucial role in reducing the spread as well as impact of the disease outbreak. Stringent regulations have been implemented by authorities to control the situation and curb economic losses.

Increasing Demand for Animal Products

There has been rising demand for animal proteins like meat, milk and eggs due to growth in world population and rise in disposable incomes in developing countries. Foot and mouth disease is one of the most contagious diseases affecting cloven-hoofed animals like cattle, swine, sheep, goats and deer. It results in formation of blisters and vesicles in the mouth and on the feet. This disease can cause considerable economic losses to farmers due to mortality in young animals and decreased milk production. Therefore, vaccination remains an important tool for farmers to protect their livestock from the disease and ensure continuous supply of animal products to meet the growing demand. Increased focus on ensuring food security boosts investments in FMD vaccines globally.

Advancements in Vaccine Technologies

Biopharmaceutical companies are continually investing in research and development of more effective FMD vaccines. Traditionally, FMD vaccines were developed using chemically inactivated whole viruses. However, newer recombinant or subunit vaccines developed using modern biotechnology have better safety profiles as compared to conventional vaccines. These second-generation vaccines not only provide robust protection against various FMD virus serotypes but are also safe for use in pregnant animals. Increasing adoption of novel vaccine production technologies like reverse genetics can reduce vaccine costs and help expand vaccine coverage to more countries and regions.

High Cost of Vaccination

While FMD vaccination remains critical for control and eradication of the disease, the high costs of vaccination can hinder its widespread adoption in developing and underdeveloped regions where outbreaks are more common. The primary vaccination involves annual immunization of large herds which requires substantial financial resources. Even for subsistence farmers in rural areas, the direct and indirect costs of vaccination like cold chain logistics, labor and lost productivity days can be prohibitive. This cost hurdle restricts the ability of farmers and national control programs to scale up vaccination coverage uniformly across all regions and populations at risk.

Vaccine Supply Chain Challenges

Effective delivery and administration of FMD vaccines require an uninterrupted cold chain from production facilities to the site of vaccination. However, developing countries lacking reliable temperature-controlled infrastructure face major challenges in the cross-country/regional distribution of vaccines. Issues like cold chain breaks, stock-outs, shortage of trained personnel and lack of coordination between private/public sector stakeholders can disrupt the supply chain. The complex logistics of coordinating mass vaccination campaigns across dispersed, remote farming communities can hamper the market growth. Any breakdown during storage or transport can compromise vaccine efficacy and benefit-cost ratio. The inconsistent supply chain networks, especially in tropical and subtropical countries, can hamper the market expansion to certain regions.

Growing Livestock Industry in Asia

Asia Pacific accounts for over 60% of the world’s cattle, buffalo and sheep population. Rapid economic development and rising disposable incomes boosts demand for animal protein in the region. This, coupled with initiatives by governments to boost domestic livestock production, can lead to strong growth of the livestock industry across Southeast Asia, South Asia and China over the coming decade. As disease control becomes a priority for ensuring stable livestock supplies and gaining access to international export markets, there will be huge demand for veterinary products including FMD vaccines.

Demand from Middle East and Africa

Outbreaks of FMD in the Middle East and Africa regions are of global economic significance due to interconnected global trade in animals and animal products. While countries in these regions already constitute major existing markets, control programs in many nations are still at a nascent stage. Improvements in logistics networks, economic development and commitments under regional/international disease eradication initiatives are anticipated to boost FMD vaccination rates over the next five years. This offers opportunity to vaccine companies to engage more closely with countries and help strengthen their disease control capabilities.

Link - https://www.coherentmarketinsights.com/market-insight/foot-and-mouth-disease-vaccine-market-1945

Key Development

• On June 11, 2024, more than 1.95 lakh cattle in Kanniyakumari and Tenkasi districts will receive foot and mouth disease vaccinations over the next three weeks. The disease, transmitted through close contact in sheds, causes fever and blisters in affected animals. Vaccinating 60,000 bulls, cows, and buffaloes aims to prevent fatalities and safeguard milk productivity, thus, benefiting farmers.
• In August 2022, the National Animal Disease Control Programme on foot and mouth disease (NADCP) was initiated by the Nagaland Government in India
• In June 2022, the prevalence of foot and mouth disease in cattle increased to over 151,000, prompting the Indonesian government to initiate a livestock immunization campaign
• In March 2022, a Tunisia-based virology lab confirmed the strain of foot and mouth disease (FMD) in cows through genetic sequencing facilitated by the FAO and IAEA. The Joint FAO/IAEA Centre's free sequencing service, launched in 2018, has processed over 5,300 samples from 24 countries, detecting various pathogens including African swine fever, avian influenza, and coronavirus.

Key Players: Bayer AG, Boehringer Ingelheim International GmbH, Merck & Co., Inc. (MSD Animal Health), Indian Immunologicals Ltd., Limber Laboratories Pvt. Ltd., Brilliant Bio Pharma Private Limited, Inova Biotechnologia Saúde Animal Ltda., Biovet Vaxxinova, Veterquímica S.A., MEVAC, Agrovet, Biogénesis Bagó, FGBI - Federal Centre for Animal Health, Vecol S.A., Laboratorios Agrovet S.A., Centro Diagnóstico Veterinario, Razi Vaccine & Serum Research Institute, VETAL Animal Health Veterinary Pharmaceuticals.